Admin
Categories
- 3922 – lorlatinib by Pfizer
- alectinib – Alecensa from Chugai – Roche – GenenTech
- Anaplastic Large-Cell Lymphomas
- AP26113 – brigatinib from Ariad
- ASP3026 from Astellas
- Brain metastases
- CEP-37440
- ceritinib – Zykadia from Novartis
- crizotinib – Xalkori from Pfizer
- Experiences
- Glioblastomas
- Imunotherapies
- JH-VIII-157-02
- Lung cancer
- Neuroblastomas
- NMS-E628
- PLB1003 – Beijing Pearl Biotechnology
- Potential Treatments
- Regulatory applications & approvals
- Research
- Resistance to treatment
- RXDX-101 – entrectinib – by Ignyta
- Side Effects
- TPX-0005: TP Therapeutics
- TSR-011 from Tesaro
- Uncategorized
- X-396 – ensartinib from Xcovrery
Category Archives: 3922 – lorlatinib by Pfizer
Pfizer update
Pfizer announced that in 2015 the are going to start trials that combine imunitherapy (PDL-1 and PD-1) drugs with its two ALK inhibitor drugs. Pfizer is planning a potential pivotal study of PF-06463922 starting in 2015. By the end of … Continue reading